OncoSec Medical Incorporated (ONCSQ)
OTC PINK OTC PINK Primary Summary
OncoSec Medical Incorporated (ONCSQ) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has OncoSec Medical Incorporated ever had a stock split?
OncoSec Medical Incorporated Profile
| Biotechnology Industry | Healthcare Sector | - CEO | OTC PINK Exchange | 68234L405 CUSIP |
| US Country | 40 Employees | - Last Dividend | 9 Nov 2022 Last Split | - IPO Date |
Overview
OncoSec Medical Incorporated established itself as a distinguished late-stage immuno-oncology entity, with its efforts concentrated on the invention, development, and commercialization of intra-tumoral DNA-based treatments aimed at stimulating and enhancing anti-tumor immune responses for cancer therapy. This innovative approach showcased a dedication to addressing the complex challenges of cancer treatment through cutting-edge technology and collaboration. Originating as NetVentory Solutions Inc, the company underwent a strategic rebranding to OncoSec Medical Incorporated in March 2011, marking a pivotal shift towards its current focus. Despite its groundbreaking work in the field, OncoSec faced significant challenges, ultimately leading to the filing of a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of New Jersey on June 14, 2023. The company was headquartered in Pennington, New Jersey, and has been part of pivotal clinical trial collaborations, including those with Merck & Co., Inc., and esteemed academic institutions like Duke University's Center for Applied Therapeutics.
Products and Services
- KEYNOTE-695 - Engaged in a Phase 2 trial, this product aims at the treatment of advanced melanoma, representing OncoSec's commitment to addressing this challenging form of cancer through innovative DNA-based therapeutics.
- TAVO + SARS-CoV-2 spike glycoprotein - This unique combination, currently in a Phase 1 clinical trial, represents an inventive application of OncoSec’s technology, targeting the treatment of COVID-19 and showcasing the company’s flexibility in addressing global health crises.
- TAVO + epacadostat + pembrolizumab - In Phase 1 clinical trial, this combination is geared towards the treatment of squamous cell carcinoma head and neck cancer, demonstrating OncoSec's dedication to fighting diverse cancer types through collaborative research and development.
- TAVO + nivolumab - Currently in a Phase 2 clinical trial, this product is aimed at the treatment of breast cancer, indicating OncoSec’s commitment to broadening its impact across various cancer domains.
- TAVO + CXCL9 - This combination is being explored for the treatment of solid tumors, reflecting OncoSec’s ongoing efforts to expand its therapeutic reach and impact in the oncology field.
- OMS-100 and OMS-102 - Both in Phase 2 clinical trials for the treatment of metastatic melanoma, these products exemplify OncoSec's concentrated efforts on melanoma, striving to offer new hope through pioneering treatments.
OncoSec’s clinical and research collaborations, especially with Merck & Co., Inc., and Duke University, underscore its strategic approach towards leveraging partnerships to accelerate the development and potential commercialization of its promising therapeutic pipeline.
